The authors concluded that the placebo response rate in controlled trials of patients with gastro-oesophageal reflux disease was substantial; it appeared to be independent of erosive/non-erosive oesophagitis, but related to the class of acid suppression treatment studied. These conclusions appeared to reflect the evidence, but incomplete review methodology reporting and differences between trials make it difficult to assess their reliability.
Study selection
Double-blind, placebo-controlled randomised controlled trials (RCTs) of at least 20 patients who received acute treatment for gastro-oesophageal reflux disease with either a proton-pump inhibitor or an H 2 -receptor antagonist for at least two weeks were eligible for inclusion. Eligible trials had to report relief of heartburn on the final day of the trial as a primary outcome. Trials were required report the number of patients responding (with relief of heartburn), provide an explicit definition of relief of heartburn, and restrict co-interventions for reflux except for rescue treatments (but excluding antisecretory drugs).
The included trials compared placebo with proton-pump inhibitors (dexlansoprazole MR, esomeprazole, omeprazole, pantoprazole or rabeprazole) or H 2 -receptor antagonists (cimetidine, famotidine, nizatidine and ranitidine). The frequency of treatment generally ranged from one to twice daily. Most trials involved patients with non-erosive reflux disease; other trials included patients with erosive oesophagitis, or both erosive and non-erosive disease. Most trials were in patients of Caucasian or mixed ethnicity. The median age of patients was 49 years (range 18 to 85 years); just over half were women. Included trials used different definitions for relief of heartburn that ranged from 'complete relief or resolution of 24-heartburns' to 'sufficient or substantial control of heartburn' to 'complete relief of upper gastrointestinal symptoms'. The included trials were conducted between 1983 and 2009. The review also separately analysed trials that compared endoscopic procedures with placebo treatment in patients with gastro-oesophageal reflux disease, but it was not clear if this was part of a systematic review, so these data were not summarised in this abstract.
The authors did not state how papers were selected for the review.
Assessment of study quality
Three reviewers independently assessed trial quality using the Jadad criteria (reporting of randomisation, blinding and withdrawals). Disagreements were resolved by a fourth reviewer.
Data extraction
Three reviewers independently extracted sufficient data to permit calculation of an odds ratio (OR) with 95% confidence interval (CI). Placebo and treatment response rates and standard deviations (SDs) were calculated for each study. Disagreements were resolved by a fourth reviewer.
Methods of synthesis
Pooled odds ratios and 95% confidence intervals were calculated using a random-effects model. Statistical heterogeneity was assessed using the Q statistic and the I 2 statistic. Subgroup analysis was conducted to examine the
